Omeros Co. (NASDAQ:OMER - Get Free Report) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 8,920,000 shares, a decline of 16.9% from the November 15th total of 10,730,000 shares. Currently, 16.1% of the company's shares are sold short. Based on an average daily volume of 701,200 shares, the short-interest ratio is presently 12.7 days.
Institutional Trading of Omeros
A number of institutional investors and hedge funds have recently bought and sold shares of OMER. Geode Capital Management LLC boosted its stake in shares of Omeros by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company's stock valued at $5,318,000 after purchasing an additional 6,839 shares during the period. State Street Corp lifted its holdings in Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock worth $4,867,000 after buying an additional 3,839 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Omeros by 4.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company's stock valued at $1,926,000 after buying an additional 18,454 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company's stock worth $887,000 after acquiring an additional 31,081 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company's stock valued at $454,000 after acquiring an additional 6,435 shares in the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several analysts have recently weighed in on the stock. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Thursday, November 14th. RODMAN&RENSHAW upgraded Omeros to a "strong-buy" rating in a research report on Thursday, November 14th. Cantor Fitzgerald restated a "neutral" rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com upgraded Omeros from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Rodman & Renshaw started coverage on Omeros in a research report on Thursday, November 14th. They set a "buy" rating and a $9.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.
Read Our Latest Stock Report on Omeros
Omeros Trading Down 10.1 %
Omeros stock traded down $0.86 during trading on Friday, hitting $7.63. The company had a trading volume of 1,096,373 shares, compared to its average volume of 518,327. The company's 50 day simple moving average is $6.61 and its 200-day simple moving average is $5.00. Omeros has a 1-year low of $2.61 and a 1-year high of $12.65. The stock has a market cap of $442.16 million, a price-to-earnings ratio of -3.30 and a beta of 1.97.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
See Also
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
